Phase 2 N=114 N-acetylcysteine for Tobacco Use Disorder
Nicotine Dependence · Smoking
Primary: Number of Participants With Biochemically-verified Abstinence From Smoking on Days 1-3 of the Protocol. — 8; 6 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=326 Low Nicotine Content Cigarettes in Vulnerable Populations: Opioid Use Disorder
Tobacco Use Disorder
Primary: Number of Cigarettes Smoked Per Day — 22.54; 14.32; 11.76; 7.63 cigarettes per day
Phase 2 N=326 Low Nicotine Content Cigarettes in Vulnerable Populations: Affective Disorders
Tobacco Use Disorder
Primary: Cigarettes Per Day — 22.54; 14.32; 11.76; 7.63 cigarettes per day
Phase 4 N=47 Nicotine Replacement Therapy in the Intensive Care Unit
Delirium · Psychomotor Agitation · Substance Withdrawal Syndrome
Primary: 30-day Mortality — 9.5; 7.7 percentage of patients
Phase 2 N=11 Suvorexant to Reduce Symptoms of Nicotine Use
Smoking Cessation
Primary: Stress as Assessed by a Visual Analog Scale (VAS) for Stress — 3.4; 3 score on a scale
N/A N=137 Varenicline and Motivational Advice for Smokers With Substance Use Disorders
Smoking Cessation · Nicotine Dependence
Primary: 7-day Point-prevalence Smoking Abstinence — 2; 10 participants — p=<0.05
Phase 3 N=52 Highdose Nicotine Patch Therapy for Smokeless Tobacco Use
Smokeless Tobacco Use
Primary: End of Treatment (Week 8) Point Prevalence Abstinence — 11; 6 participants — p=0.05
Phase 2 N=40 Varenicline for Treatment of E-cigarette Dependence
Smoking Cessation
Primary: Number of Participants Abstinent From Vaping at Week 8 — 9; 6 Participants
Phase 4 N=127 Nicotine Patch for Marijuana Withdrawal
Marijuana Dependence
Primary: Profile of Mood Scale Total Negative Affect (Tension + Depression + Anger) — 8.52; 8.096; 5.14; 4.615 units on a scale
N/A N=36 Treatment for Nicotine Addiction in Women
Nicotine Dependence
Primary: Withdrawal Symptoms (MNWS Score) — 13.33; 9.40; 11.95; 13.29 score on a scale — p=0.18
Phase 4 N=20 Treatment of Nicotine Dependence and Acute Depression
Major Depressive Disorder · Nicotine Dependence
Primary: Hamilton Depression Scale Score — -.5322 percentage of change in depression — p=<.001
Phase 2 N=67 Translational Neuropsychopharmacology Research of Nicotine Addiction
Nicotine Dependence, Cigarettes
Primary: Percent Change in Blood Oxygen Level Dependent (BOLD) Signal Response — -0.09; 1.07; 0.08; 1.19 Percentage change
Phase 2 N=28 N-Acetyl Cysteine Plus Behavioral Therapy for Nicotine Dependent Pathological Gamblers
Gambling · Tobacco Use Disorder
Primary: Yale-Brown Obsessive Compulsive Scale Modified for Pathological Gambling Total Score — 23.5; 20.4 units on a scale
Phase 2 N=29 Depressed Mood Improvement Through Nicotine Dosing 2
Depressive Disorder
Primary: MADRS (Montgomery Asberg Depression Rating Scale) Score Change — -15.4 units on a scale — p=< 0.001
Phase 2 N=24 Effects of Semaglutide on Nicotine Intake
Tobacco Use Disorder · Nicotine Addiction
Primary: Change in Nicotine Self-Administration — -0.8; -0.5 Number of cigarettes
Phase 2 N=72 Varenicline Treatment for Cannabis Use Disorder
Substance Use Disorder
Primary: Cannabis Withdrawal Symptoms During Active Treatment — 2.23; 3.94; 2.59; 4.07 score on a scale
Phase 2 N=49 Impact of Nicotine Reduction on Adolescent Cigarette Use, Alternative Tobacco Use, and Harm From Tobacco
Nicotine Dependence, Cigarettes, Uncomplicated
Primary: Average Cigarettes Smoked Per Day — 4.3; 8.0 average cigarettes per day — p=.111
Phase 2 N=75 Nicotine and Sensorimotor Replacement for Smoking in Smokers With Schizophrenia
Tobacco Use Disorder · Schizophrenia
Primary: Preferred Brand Smoke Intake (CO) — 3.30; 3.16; 9.07; 10.54 ppm
N/A N=65 Supplemental Nicotine Administration for Smoking Cessation in Posttraumatic Stress Disorder (PTSD)
Smoking Cessation
Primary: Participants Self-reporting Abstinence During 6 Weeks Post Quit — 16; 13 participants
N/A N=56 Medicinal Nicotine for Preventing Cue Induced Craving
Tobacco Use Disorder
Primary: Craving Symptom Severity Score Assessed Via Questionnaire — 0.52; 0.57; 0.31 units on a scale — p=0.25
N/A N=188 Reduced Nicotine Cigarettes in Smokers With Mood and Anxiety Disorders
Tobacco Dependence
Primary: Plasma Cotinine Concentration — 82.8; 259.0 ng/mL — p=<0.0001
Phase 2 N=40 Daily Liraglutide for Nicotine Dependence
Smoking Cessation · Weight, Body
Primary: Number of Participants With 7-day Point Prevalence Smoking Abstinence at 12 Weeks Post-Target Quit Date — 2; 2 Participants
N/A N=369 Cessation in Non-Daily Smokers
Smoking
Primary: Smoking Cessation, Continuous 6-month Abstinence — 13; 10 Participants — p=0.46
Phase 3 N=270 Nicotine Lozenges for Treatment of Smokeless Tobacco Addiction
Smokeless Tobacco Use
Primary: Prolonged Smokeless Tobacco Abstinence at 3 Months — 65; 41 Participants — p=<0.05
Phase 2 N=34 Restoring Cognitive Control (ReCon) in Acute Nicotine Withdrawal
Impulse Control Disorders
Primary: Safety and Tolerability of SXC-2023. — 0; 0; 0; 0 Events
N/A N=794 Impact of Nicotine Messaging on Nicotine Beliefs and Tobacco Use Behavior
Nicotine Dependence, Cigarettes
Primary: Nicotine Beliefs — 7.5; 7.8; 10.9; 11.3 score on a scale
Phase 4 N=42 Nicotine Receptor Density & Response to Nicotine Patch: Pt 2 Extended Treatment
Smoking Cessation · Schizophrenia
Primary: Exhaled Carbon Monoxide (CO) as Parts Per Million (PPM) — 11.5; 12.3; 12.0; 7.8 ppm
N/A N=24 User Acceptability of a Nicotine Lactate Delivery System (P3L)
Smoking
Primary: Change From Baseline Plasma Concentration of Nicotine/Cotinine After Each ad Libitum Use Session. — 1.7621; 2.4113; 1.9446; 5.5571 (ng/mL)
N/A N=25 Nicotine Receptor Levels and Smoking Cessation
Smoking Cessation · Nicotine Addiction
Primary: Acetylcholinergic Nicotine Receptor Availability as Determined by 2FA -PET Brain Imaging. — 17.5; 26.8 Distribution Volume Ratio (Vt/fp) — p=0.037
N/A N=31 Impact of Exclusive Use of Low Nicotine Cigarettes on Compensatory Smoking
Smoking
Primary: Breath Sample (Expired Carbon Monoxide) — 18.77; 31.07; 25.38; 30.49 parts per million — p=0.92